Telemedicine has skyrocketed during the COVID-19 pandemic, but what actions are needed for more patients to have equitable, fair access to genetics services via telegenetics?
Telemedicine has skyrocketed during the COVID-19 pandemic, but what actions are needed for more patients to have equitable, fair access to genetics services via telegenetics?
To address this urgent problem, the Advocacy and Government Affairs Committee of the American College of Medical Genetics and Genomics (ACMG) just released a new Points to Consider statement that will assist policymakers tasked with improving appropriate, broad access to genetics services via telehealth: "Considerations for Policymakers to Improve Healthcare through Telegenetics: A Points to Consider Statement of the American College of Medical Genetics and Genomics."
"We have seen a dramatic increase in telemedicine use during the COVID-19 pandemic, but research suggests access is not equitable across different population groups," said lead author Heather E. Williams, PhD, MS, in a release. "Policy efforts to ensure equitable access to genetics services via telehealth are necessary. We can continue to address disparities by eliminating barriers to accessing the medical genetics workforce."
The statement, the first published by ACMG's Advocacy and Government Affairs (AGA) Committee, is intended to be used by policymakers to consider as they pursue legislative, regulatory, or other policies related to telegenetics or reducing disparities in access to genetic services. It describes telegenetics services, the need for these services, existing barriers to technology access, actions needed to ensure equitable access and the current state of reimbursement for these services.
A few of the specific points to consider include:
The statement concludes that while the COVID-19 pandemic expedited the expanded integration of telemedicine into genetic services, only a concerted effort will ensure that all Americans can benefit from these services. The points discussed in this statement should be viewed as considerations for federal, state and institutional policymakers as well as payers that are tasked with ensuring equitable access to telemedicine, including telegenetics. Improved telehealth policies are necessary to enhance patient care and reduce disparities in accessing genetics healthcare to patients throughout the United States.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Opzelura May Reduce Need for Other Treatments in Atopic Dermatitis | AAD 2025
March 11th 2025Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics during the 12 months after treatment with the topical nonsteroidal, finds study at American Academy of Dermatology Association annual meeting.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Supporting Patients with Type 1 Diabetes Through Education, Technology and Transparency
March 10th 2025Arti Masturzo, M.D., chief medical officer of CCS, spoke with MHE in this third part of a video series to share how CCS helps patients with type 1 diabetes effectively use glucose monitors and insulin pumps by providing clear guidance and troubleshooting support, recognizing that even minor errors in management can have significant health consequences.
Read More
Melanoma Treatment Advances Now Crossing into Other Skin Cancers
March 10th 2025Deborah S. Sarnoff, M.D., talks about the recent breakthrough treatments that are paving the way to treat patients with advanced basal cell carcinoma, squamous cell carcinoma and Merkel cell carcinoma, which is a rare and aggressive type of skin cancer.
Read More